>> AVI licensed its vascular disease program to the Cook Group Inc. (Cook) in March 2006 for device delivery of the NeuGene® antisense drug AVI–4126, while the company is focusing internal development on coronary artery bypass graft (CABG) using AVI–5126. <<
>By the way, what ever happened to Resten-NG?<
An entire chapter in the book Biotech Fiascos will be devoted to answering this. (Just kidding.) I would give the details, but I am suffering from PTASD (Post-Traumatic AVII-Shareholder Disorder.)